David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.
In a brief SEC filing, the biotech said he had “delivered his resignation […] effective December 28, 2017.”
The brief update said he was leaving to “pursue another professional opportunity,” though that was all she wrote on details. A retained search for a new CMO has begun, with help from Russell Reynolds Associates.
This comes three months after Janssen, the biotech unit of Johnson & Johnson, said it was ditching work with Achillion on a cocktail hep C program, citing a crowded market of innovative meds in this area, namely those from Gilead.
Achillion, with a market cap of around $400 million, was hit hard by the decision as the biotech was working with Janssen on its NS5A inhibitor, odalasvir, for this program in a potential $1 billion biobucks deal before the plug was pulled.
Some had seen Gilead or J&J as potential buyers of the company, but this has not come to fruition, and its shares have taken a hit since J&J’s decision to terminate its hep C deal.
Achillion is also now working on a midstage med, ACH-4471, in patients with untreated paroxysmal nocturnal hemoglobinuria (PNH).
By Ben Adams
Source: Fierce Biotech
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
